Live Roundtable: What Is the Biggest Bottleneck Holding Back Cell and Gene Therapy?

Industry leaders debate the manufacturing, regulatory, financial, and commercial barriers preventing advanced therapies from reaching more patients

1

Cell and gene therapies have demonstrated potential to transform medicine, but broad access remains challenging.
2

The discussion identifies complex manufacturing, fragmented data systems, regulatory requirements, limited care sites, and uncertain reimbursement as potential bottlenecks.
3

Experts from across the cell and gene therapy ecosystem discuss where the industry should focus its efforts.
4

The roundtable considers whether the sector is addressing the right problems and where greater collaboration is needed.
5

Participants discuss how AI and other emerging technologies could help address barriers between therapeutic innovation and patient access.

1